How to Deal With Continued Volatility

Stocks struggled again last week. While equity markets were impacted by mixed economic data, the real catalysts were at the industry level.

Volkswagen’s emissions-cheating scandal weighed down auto makers, industrial companies came under pressure after bellwether Caterpillar lowered its revenue forecast and announced job cuts, and biotech stocks traded near bear market territory after a tweet from Hillary Clinton raised the specter of price controls in that sector.

In other words, in a change from the big-picture catalysts of the past few months, markets suffered thanks to stock-specific issues.

But regardless of the cause behind last week’s selloff, the losses reinforced how the investment climate has changed in recent months. Investors are still coming to grips with how to manage something we have not seen in a while: a regime of above-average market volatility. Looking forward, investors should expect the current high volatility regime to persist, as I write in my new weekly commentary, “A Call for Quality as Volatility Turns Up the Volume.”

Other Signs Pointing to Market Volatility

The combination of slower global growth, uncertainty as to the Federal Reserve (Fed)’s future path and less benign credit market conditions suggests continued heightened volatility.

In addition, Washington may also fuel volatility in the coming week. Congress needs to pass a continuing resolution by September 30th to keep the government funded and avoid yet another government shutdown. While I don’t expect a shutdown, the risk of that scenario increased somewhat Friday following the announcement that House Speaker John Boehner will resign from Congress at the end of October.

Tips for Navigating Market Bumps

So how to contend with the rocky road ahead? Rather than attempt to time each swing, investors may be better off managing the risks embedded in their portfolio.

While value stocks are at risk should economic growth estimates continue to come down, momentum companies are exposed to more spikes in volatility, a factor that has contributed to biotech’s recent underperformance. Conversely, so-called quality stocks, which generally have strong return on equity and low debt, may be better supported should volatility continue to remain elevated.

Russ Koesterich, CFA, is the Chief Investment Strategist for BlackRock. He is a regular contributor to The Blog.

© BlackRock

© BlackRock

Read more commentaries by BlackRock  

Sponsored Content

Upcoming Virtual Events View All

August 17, 2026 at 02:00 PM EDT - 1.0 CE credit
Income vs Valuation: Why Preferreds Matter In Today’s Environment
August 18, 2026 at 02:00 PM EDT - 1.0 CE credit
Earnings, Income & Sector Opportunities: Positioning for a Changing Market Regime
August 20, 2026 at 02:00 PM EDT - 1.0 CE credit
The Rise of International Equities
August 24, 2026 at 04:30 PM EDT
In the search for yield, you have options
August 25, 2026 at 12:30 PM EDT
Navigating Macro Volatility with Energy Infrastructure
August 26, 2026 at 02:00 PM EDT - 1.0 CE credit
The secular case for emerging markets growth
August 27, 2026 at 02:00 PM EDT - 1.0 CE credit
AI for Advisors: Separating Signal from Noise
August 31, 2026 at 12:30 PM EDT
The importance of hedging foreign currency exposure in your equity portfolio
September 01, 2026 at 12:30 PM EDT
Emerging Markets Hard Currency Debt and What it Means for Your Portfolio
September 08, 2026 at 02:00 PM EDT - 1.0 CE credit
Real Assets: Powering the Next Wave of Global Growth
September 09, 2026 at 02:00 PM EDT - 1.0 CE credit
How Section 351 Can Create Tax Advantages
September 10, 2026 at 02:00 PM EDT - 1.0 CE credit
How to approach the market amid changing leadership
September 14, 2026 at 02:00 PM EDT - 1.0 CE credit
Always Invested. Always Hedged. Built for this Moment.
October 13, 2026 at 02:00 PM EDT - 1.0 CE credit
Hundreds of Billions for Nuclear: Who Actually Benefits?
November 12, 2026 at 11:00 AM EST - 1.0 CE credit
2027 Market Outlook Symposium